REMEDI4ALL: BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

REMEDI4ALL旨在通过创建一个涵盖所有相关部门和学科的充满活力的实践社区，建立欧洲在药物再利用方面的全球领导地位。REMEDI4ALL将建立和运营一个永久性的欧洲研究和创新平台，包括完整的价值链，以尖端为中心，以患者为中心的重新利用，与用户合作，在任何开发阶段执行高潜力项目，通过全面的教育和培训组合提高所有利益相关者群体的技能，并推进与所有利益相关者和思想领袖的跨部门政策对话。在REMEDI4ALL中开发的工具和流程将在4个雄心勃勃的临床前和临床阶段演示组合中进行验证，代表各种疾病领域的高患者需求，包括肿瘤学，罕见病和传染病。REMEDI4ALL平台将以目标为导向和以患者为中心的方式，将科学、方法、财务、法律、监管和知识产权方面的重新定位方法整合在一起，运行一个完整、协调和可访问的价值链。与研究资助者和患者社区密切合作，REMEDI4ALL将通过一个永久可持续的实体，与欧洲永久基础设施和合作伙伴密切合作，吸引和支持大量用户群和伴随的投资。实践社区包括领先的学术和临床设施和基础设施、药品监管机构、卫生技术评估人员、公共机构和资助者、小型和大型行业、最先进的人工智能和计算机工具，以及实现最佳知识交流的全球合作者网络。REMEDI4ALL将通过其完整的价值链和基于共识的政策制定使命，大大提高欧洲开发高质量再用途药物并将其推向市场的能力。没有公开描述

REMEDI4ALL aims to establish Europe's leadership globally in the re-purposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDI4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused re-purposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDI4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases. The REMEDI4ALL platform will operate a complete, harmonized, and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the re-purposing approach in a goal-oriented and patient-centric approach. Working closely together with research funders and the patient community, REMEDI4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDI4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into market, through its complete value chain and consensus-based policy development mission.no public description